J. Overgaard

Cancer Research · The Lancet · 2005–2021

A researcher in the Science corpus: 8 papers; trusts 4 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Cancer Research — 14 citations into it; #613 of 1,780 by trust here, #565 by citations
• Pulmonary and Respiratory Medicine — 11 citations into it
• Molecular Biology — 8 citations into it

Whom J. Overgaard trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Tatum
2. Adrian L. Harris
3. P. Vaupel
4. J. Erler

Who trusts J. Overgaard overall

1. Robert G. Bristow
2. Michael Baumann
3. Jessica A. Bertout
4. R. Hill
5. S. Mckeown

Papers from J. Overgaard's perspective

Ordered by how strongly the researchers J. Overgaard trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hypoxia — a key regulatory factor in tumour growth (Nature Reviews. Cancer)
2. Targeting HIF-1 for cancer therapy (Nature Reviews. Cancer)
3. Lysyl oxidase is essential for hypoxia-induced metastasis (Nature)
4. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. (Radiotherapy and Oncology)
5. Hypoxia in cancer: significance and impact on clinical outcome (Cancer Metastasis Review)
6. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy (International Journal of Radiation Biology)
7. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. (Journal of the National Cancer Institute)
8. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. (Cancer Research)
9. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. (Cancer Research)
10. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. (Cancer Research)

Their papers

• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group (2021)
• HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). (2016)
• Radiation oncology in the era of precision medicine (2016) — 768 citations
• Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. (2009) — 654 citations
• Hypoxic radiosensitization: adored and ignored. (2007) — 622 citations
• Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. (2006) — 1,048 citations
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. (2005) — 7,387 citations
• Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. (2005) — 942 citations